

# Geoffrey R Oxnard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11493316/publications.pdf>

Version: 2024-02-01

157  
papers

17,170  
citations

28272

55  
h-index

14758

127  
g-index

157  
all docs

157  
docs citations

157  
times ranked

16703  
citing authors

#	ARTICLE	IF	CITATIONS
1	Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. <i>Nature Medicine</i> , 2015, 21, 560-562.	30.7	1,280
2	Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. <i>Annals of Oncology</i> , 2020, 31, 745-759.	1.2	770
3	Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3375-3382.	1.6	741
4	Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA. <i>Clinical Cancer Research</i> , 2014, 20, 1698-1705.	7.0	717
5	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Journal of Clinical Oncology</i> , 2018, 36, 1631-1641.	1.6	668
6	Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1700-1709.	27.0	615
7	Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation. <i>Clinical Cancer Research</i> , 2011, 17, 1616-1622.	7.0	556
8	MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. <i>Journal of Clinical Oncology</i> , 2016, 34, 721-730.	1.6	549
9	Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay. <i>Clinical Cancer Research</i> , 2011, 17, 1169-1180.	7.0	539
10	Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR-T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. <i>JAMA Oncology</i> , 2018, 4, 1527.	7.1	522
11	Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 1014.	7.1	516
12	Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 813-824.	27.0	505
13	Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling. <i>Science Translational Medicine</i> , 2011, 3, 90ra59.	12.4	457
14	Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer. <i>Science Translational Medicine</i> , 2013, 5, 216ra177.	12.4	438
15	Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design. <i>Clinical Cancer Research</i> , 2011, 17, 6298-6303.	7.0	383
16	Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations. <i>Clinical Cancer Research</i> , 2012, 18, 1167-1176.	7.0	342
17	Institutional implementation of clinical tumor profiling on an unselected cancer population. <i>JCI Insight</i> , 2016, 1, e87062.	5.0	340
18	New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 5530-5537.	7.0	326

#	ARTICLE	IF	CITATIONS
19	False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. <i>Clinical Cancer Research</i> , 2018, 24, 4437-4443.	7.0	321
20	"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. <i>Neuro-Oncology</i> , 2011, 13, 1364-1369.	1.2	309
21	New Targetable Oncogenes in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1097-1104.	1.6	280
22	Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions. <i>Journal of Thoracic Oncology</i> , 2013, 8, 179-184.	1.1	269
23	A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1690-1700.	1.1	256
24	Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2016, 22, 915-922.	7.0	212
25	Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1726-1735.	1.1	208
26	Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC. <i>Scientific Reports</i> , 2016, 6, 33860.	3.3	189
27	Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 313.	7.1	171
28	Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes. <i>Journal of Clinical Oncology</i> , 2011, 29, 3114-3119.	1.6	136
29	Definitive Primary Therapy in Patients Presenting With Oligometastatic Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 880-887.	0.8	136
30	EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 1790-1797.	7.0	134
31	Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1334-1341.	9.4	133
32	Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. <i>Clinical Cancer Research</i> , 2020, 26, 2615-2625.	7.0	129
33	Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1901-1911.	1.1	127
34	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1242-1253.	2.5	120
35	Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. <i>Oncologist</i> , 2013, 18, 1214-1220.	3.7	119
36	When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1534-1541.	6.3	118

#	ARTICLE	IF	CITATIONS
37	Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1433-1441.	10.7	114
38	Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. <i>Cancer Research</i> , 2017, 77, 2712-2721.	0.9	110
39	Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1049-1052.	1.1	108
40	A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development. <i>Clinical Cancer Research</i> , 2010, 16, 4647-4653.	7.0	104
41	ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5439-5444.	7.0	104
42	Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 176-190.	329.8	101
43	Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms. <i>Clinical Cancer Research</i> , 2021, 27, 3094-3105.	7.0	101
44	A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. <i>Clinical Cancer Research</i> , 2016, 22, 6010-6020.	7.0	100
45	Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 56-62.	27.6	99
46	Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2015, 10, 431-437.	1.1	98
47	Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 2851-2860.	7.0	96
48	Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib. <i>Clinical Cancer Research</i> , 2021, 27, 34-42.	7.0	87
49	Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation. <i>Clinical Lung Cancer</i> , 2015, 16, e101-e104.	2.6	85
50	Application of Plasma Genotyping Technologies in Non-Small Cell Lung Cancer: A Practical Review. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1344-1356.	1.1	81
51	Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. <i>Journal of Clinical Oncology</i> , 2018, 36, 3459-3465.	1.6	79
52	Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 7351-7359.	7.0	74
53	Measurement of mesothelioma on thoracic CT scans: A comparison of manual and computer-assisted techniques. <i>Medical Physics</i> , 2004, 31, 1105-1115.	3.0	72
54	Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations. <i>Cancer Discovery</i> , 2021, 11, 591-598.	9.4	69

#	ARTICLE	IF	CITATIONS
55	Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA. <i>Lung Cancer</i> , 2019, 134, 96-99.	2.0	67
56	Intracranial Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4160-4167.	7.0	64
57	Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer. <i>JAMA Oncology</i> , 2017, 3, 740.	7.1	61
58	Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA. <i>Clinical Cancer Research</i> , 2021, 27, 4221-4229.	7.0	61
59	The cellular origins of drug resistance in cancer. <i>Nature Medicine</i> , 2016, 22, 232-234.	30.7	58
60	EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1995-2002.	1.1	58
61	Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in <i>EGFR</i> -Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib. <i>Clinical Cancer Research</i> , 2011, 17, 6322-6328.	7.0	57
62	Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. <i>Lung Cancer</i> , 2006, 52, 141-148.	2.0	55
63	Circulating tumor DNA analysis in the era of precision oncology. <i>Oncotarget</i> , 2020, 11, 188-211.	1.8	54
64	Clinical Implications of Variant ALK FISH Rearrangement Patterns. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1648-1652.	1.1	52
65	The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. <i>Cancers</i> , 2021, 13, 3501.	3.7	50
66	EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. <i>Clinical Cancer Research</i> , 2018, 24, 6548-6555.	7.0	49
67	Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non-Small-Cell Lung Cancer With Brain Metastases. <i>JAMA Oncology</i> , 2017, 3, 1274.	7.1	46
68	Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping. <i>Lung Cancer</i> , 2018, 122, 72-75.	2.0	46
69	Realizing the Potential of Plasma Genotyping in an Age of Genotype-Directed Therapies. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju214-dju214.	6.3	44
70	Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis. <i>JAMA Oncology</i> , 2022, 8, 385.	7.1	44
71	Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. <i>Cancer</i> , 2015, 121, 2570-2577.	4.1	42
72	Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study. <i>Journal of Clinical Oncology</i> , 2018, 36, 12003-12003.	1.6	40

#	ARTICLE	IF	CITATIONS
73	Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Network Open</i> , 2022, 5, e225394.	5.9	37
74	Non-small Cell Lung Cancer in Octogenarians: Treatment Practices and Preferences. <i>Journal of Thoracic Oncology</i> , 2007, 2, 1029-1035.	1.1	35
75	Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors. <i>JAMA Oncology</i> , 2016, 2, 772.	7.1	34
76	Evaluation of Semiautomated Measurements of Mesothelioma Tumor Thickness on CT Scans <sup>1</sup> . <i>Academic Radiology</i> , 2005, 12, 1301-1309.	2.5	33
77	Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216). <i>JAMA Oncology</i> , 2022, 8, 717.	7.1	32
78	Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2014, 120, 2289-2298.	4.1	30
79	Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. <i>Cancer Research</i> , 2015, 75, 3139-3146.	0.9	30
80	Precision Medicine in Non-small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 708-715.	3.8	30
81	Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2509-2509.	1.6	30
82	Use of <i>Ex Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2393-2403.	7.0	27
83	Enhanced Ratio of Signals Enables Digital Mutation Scanning for Rare Allele Detection. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 284-292.	2.8	26
84	A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations. <i>Clinical Cancer Research</i> , 2017, 23, 7467-7473.	7.0	26
85	Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. <i>Lung Cancer</i> , 2020, 140, 35-41.	2.0	22
86	Delay of chemotherapy through use of post-progression erlotinib in patients with <i>EGFR</i> -mutant lung cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7547-7547.	1.6	22
87	The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2022, 28, 728-737.	7.0	20
88	Strategies for Overcoming Acquired Resistance to Epidermal Growth Factor Receptor-Targeted Therapies in Lung Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 1205-1209.	2.5	18
89	Does TMB Impact the Effectiveness of TKIs in <i>EGFR</i> -Mutant NSCLC?. <i>Clinical Cancer Research</i> , 2019, 25, 899-900.	7.0	18
90	Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation. <i>Clinical Cancer Research</i> , 2020, 26, 6464-6474.	7.0	16

#	ARTICLE	IF	CITATIONS
91	Genome-wide cell-free DNA (cfDNA) methylation signatures and effect on tissue of origin (TOO) performance.. Journal of Clinical Oncology, 2019, 37, 3049-3049.	1.6	16
92	Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer. European Urology, 2022, 81, 37-47.	1.9	16
93	Activity of erlotinib when dosed below the maximum tolerated dose for EGFR mutant lung cancer: Implications for targeted therapy development. Cancer, 2016, 122, 3456-3463.	4.1	15
94	Effective Cancer Genotyping—Many Means to One End. Clinical Cancer Research, 2019, 25, 4583-4585.	7.0	15
95	Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. Molecular Oncology, 2021, 15, 27-42.	4.6	15
96	Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology. JCO Clinical Cancer Informatics, 2018, 2, 1-12.	2.1	14
97	Does Testing Error Underlie Liquid Biopsy Discordance?. JCO Precision Oncology, 2019, 3, 1-3.	3.0	14
98	Germline Mutations in Driver Oncogenes and Inherited Lung Cancer Risk Independent of Smoking History. Journal of the National Cancer Institute, 2014, 106, djt361-djt361.	6.3	13
99	Identification of a RAS-activating TMEM87A-RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 4072-4079.	7.0	13
100	Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. Oncology, 2010, 24, 392-9.	0.5	13
101	Acquired Resistance to Targeted Therapies in Advanced Non-Small Cell Lung Cancer: New Strategies and New Agents. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e272-e278.	3.8	12
102	Early Intervention in Lung Cancers With Rapid Plasma Genotyping for EGFR and KRAS Mutations—Reply. JAMA Oncology, 2016, 2, 1096.	7.1	12
103	Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC. JCO Precision Oncology, 2021, 5, 393-402.	3.0	12
104	Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns. JCO Precision Oncology, 2021, 5, 1354-1376.	3.0	12
105	Acquired Resistance to Targeted Therapies in Advanced Non-Small Cell Lung Cancer: New Strategies and New Agents. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e272-e278.	3.8	12
106	Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials. Chinese Clinical Oncology, 2015, 4, 37.	1.2	12
107	Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). Immunotherapy, 2021, 13, 727-734.	2.0	11
108	Prevalence of UV Mutational Signatures Among Cutaneous Primary Tumors. JAMA Network Open, 2022, 5, e223833.	5.9	11



#	ARTICLE	IF	CITATIONS
109	Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis. <i>JCO Precision Oncology</i> , 2020, 4, 1098-1108.	3.0	10
110	Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial. <i>European Radiology</i> , 2021, 31, 1853-1862.	4.5	10
111	Genomic immunotherapy (IO) biomarkers detected on comprehensive genomic profiling (CGP) of tissue and circulating tumor DNA (ctDNA).. <i>Journal of Clinical Oncology</i> , 2021, 39, 2541-2541.	1.6	10
112	Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer. <i>Science Translational Medicine</i> , 2021, 13, eabb3738.	12.4	10
113	Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8015-8015.	1.6	10
114	Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer. <i>Prostate</i> , 2022, 82, 867-875.	2.3	10
115	Power in Numbers: Meta-analysis to Identify Inhibitor-Sensitive Tumor Genotypes. <i>Clinical Cancer Research</i> , 2013, 19, 1634-1636.	7.0	9
116	Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors. <i>Clinical Lung Cancer</i> , 2018, 19, e655-e665.	2.6	7
117	Traditional Diagnostics versus Disruptive Technology: The Role of the Pathologist in the Era of Liquid Biopsy. <i>Cancer Research</i> , 2020, 80, 3197-3199.	0.9	7
118	The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100194.	1.1	7
119	Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C. <i>Targeted Oncology</i> , 2021, 16, 339-355.	3.6	6
120	Abstract 2231: Utility of plasma tumor fraction (TF) to inform sensitivity of FoundationOne Liquid CDx (F1LCDx). <i>Cancer Research</i> , 2021, 81, 2231-2231.	0.9	6
121	An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scans. <i>European Journal of Cancer</i> , 2022, 161, 138-147.	2.8	6
122	Response Phenotype As a Predictive Biomarker to Guide Treatment With Targeted Therapies. <i>Journal of Clinical Oncology</i> , 2013, 31, 3739-3741.	1.6	5
123	Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program. <i>Oncology and Therapy</i> , 2018, 6, 45-58.	2.6	5
124	Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer. <i>Cancer</i> , 2021, 127, 4557-4564.	4.1	5
125	The Circulating Cell-free Genome Atlas (CCGA) Study: Follow-up (F/U) on non-cancer participants with cancer-like cell-free DNA signals.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5574-5574.	1.6	5
126	Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCR. <i>Methods in Molecular Biology</i> , 2018, 1768, 193-207.	0.9	4



#	ARTICLE	IF	CITATIONS
127	High Sensitivity of Plasma Cell-Free DNA Genotyping in Cases With Evidence of Adequate Tumor Content. <i>JCO Precision Oncology</i> , 2021, 5, 921-930.	3.0	4
128	Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus chemotherapy benefit in first-line metastatic urothelial carcinoma: A real-world study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 547-547.	1.6	4
129	Detection of EGFR mutations in non-small cell lung cancer by droplet digital PCR. <i>PLoS ONE</i> , 2022, 17, e0264201.	2.5	4
130	The Radiologic Measurement of Mesothelioma. <i>Hematology/Oncology Clinics of North America</i> , 2005, 19, 1053-1066.	2.2	3
131	Detection and clearance of <i>RET</i> variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9048-9048.	1.6	3
132	Refining the sensitivity of plasma cell-free DNA (cfDNA) genotyping by controlling for plasma tumor content.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9071-9071.	1.6	3
133	CtDNA shed as a tool to select immune checkpoint inhibitors (ICPI) with or without chemotherapy for patients (pts) with advanced non-small cell lung cancer (aNSCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9045-9045.	1.6	3
134	Real-world (rw) analysis of quantitative <i>MET</i> copy number (CN) as a biomarker in NSCLC.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9123-9123.	1.6	3
135	Reply to E.M. Gilles. <i>Journal of Clinical Oncology</i> , 2012, 30, 117-117.	1.6	2
136	Hereditary Lung Cancer Risk: Recent Discoveries and Implications for Genetic Counseling and Testing. <i>Current Genetic Medicine Reports</i> , 2018, 6, 83-88.	1.9	2
137	Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms.. <i>Journal of Clinical Oncology</i> , 2021, 39, 25-25.	1.6	2
138	SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100151.	1.1	2
139	ERBB2 copy number (CN) as a quantitative biomarker for real-world (RW) outcomes to anti-HER2 therapy in advanced gastroesophageal adenocarcinoma (adv GEA).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4045-4045.	1.6	2
140	Real-world (rw) clinical outcomes on alpelisib (ALP) in patients (pts) with breast cancer (BC) and <i>PIK3CA</i> mutations ( <i>PIK3CAm</i> ).. <i>Journal of Clinical Oncology</i> , 2021, 39, 1068-1068.	1.6	2
141	Prediction of lung cancer genotype noninvasively using droplet digital PCR (ddPCR) analysis of cell-free plasma DNA (cfDNA).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8059-8059.	1.6	2
142	Molecular residual disease (MRD) detection with a tissue comprehensive genomic profiling (CGP)-informed personalized monitoring assay: An exploratory analysis of the IMvigor-010 observation arm.. <i>Journal of Clinical Oncology</i> , 2022, 40, 448-448.	1.6	2
143	Genomic evolution from hormonal therapies and suitability of prostate cancer diagnostic specimens for metastatic prostate cancer (mPC) genomic stratification.. <i>Journal of Clinical Oncology</i> , 2022, 40, 143-143.	1.6	2
144	Radiologic Assessment of Mesothelioma. , 2005, , 433-453.		1

#	ARTICLE	IF	CITATIONS
145	Abstract 4342: Ultra-deep next generation sequencing (NGS) of plasma cell-free DNA (cfDNA) from patients with advanced lung cancers: results from the Actionable Genome Consortium. , 2016, , .		1
146	Implementation of clinical next-generation sequencing (NGS) of non-small cell lung cancer (NSCLC) to identify EGFR amplification as a potentially targetable oncogenic alteration.. Journal of Clinical Oncology, 2014, 32, 8090-8090.	1.6	1
147	Liquid biopsy (LB)-based comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) for the evaluation of patients with myeloid neoplasms.. Journal of Clinical Oncology, 2022, 40, e19064-e19064.	1.6	1
148	Clinical and genomic characteristics of pts with durable benefit from immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (aNSCLC).. Journal of Clinical Oncology, 2022, 40, 9048-9048.	1.6	1
149	Genomic landscape of acquired resistance to targeted therapies in patients with solid tumors: A study from the National Center for Precision Medicine (PRISM).. Journal of Clinical Oncology, 2022, 40, 3016-3016.	1.6	1
150	Landscape of homologous recombination reversion mutations in pancreaticobiliary malignancies.. Journal of Clinical Oncology, 2022, 40, 4156-4156.	1.6	1
151	Landscape of homologous recombination reversion mutations in gynecologic malignancies.. Journal of Clinical Oncology, 2022, 40, 5576-5576.	1.6	1
152	Commentary. Clinical Chemistry, 2015, 61, 586-587.	3.2	0
153	Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline EGFR T790M Mutation. JTO Clinical and Research Reports, 2021, 2, 100146.	1.1	0
154	Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus taxane chemotherapy benefit in metastatic castration-resistant prostate cancer: A real-world biomarker study.. Journal of Clinical Oncology, 2022, 40, 162-162.	1.6	0
155	A real-world (rw) evidence study quantifying the clinical value of multi-gene testing in early-stage lung adenocarcinoma (LUAD).. Journal of Clinical Oncology, 2022, 40, 8525-8525.	1.6	0
156	Biomarker associations of immune checkpoint inhibitor versus chemotherapy effectiveness in first-line metastatic endometrial carcinomas: A real-world study.. Journal of Clinical Oncology, 2022, 40, 5596-5596.	1.6	0
157	Utility of liquid biopsy (LB)-based comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) in lymphomas and plasma cell neoplasms.. Journal of Clinical Oncology, 2022, 40, e19543-e19543.	1.6	0